#AACR20 Final analysis of IMpower 150 (1L carbo, paclitaxel, bevacizumab, atezolizumab in NSCLC) presented by Dr. Mark Socinski, @fedcappuzzo @TonyMok9 @delvysra and others. Some interesting subset analyses in this trial. #LCSM #OncoAlert
#AACR20 A look at study design. Arm B was the four drug regimen which offered an OS improvement over Arm C (carbo/pac/bev, ECOG 4599). Here, we see comparison of A vs C (carbo/pac/bev vs carbo/pac/atezo). #LCSM #OncoAlert
#AACR20 In the final analysis, no significant difference between arms A and C (carbo/pac/atezo vs carbo/pac/bev), but the 4-drug regimen of carbo/pac/bev/atezo still offerering OS benefit. #LCSM #OncoAlert
#AACR20 IMpower 150 was one of the few to include patients with #EGFR mutations and in that subset, the 4 drug regimen of carbo/pac/bev/atezo improved OS (HR 0.60) whereas carbo/pac/atezo without bev did not (HR 1.00). Imperfect data, yes, but quite interesting. #LCSM #OncoAlert
#AACR20 Similarly, it was the VEGF/PDL1 combination that led to improved outcomes in patients with liver metastases (carbo/pac/bev/atezo OS HR 0.67) whereas PDL1 without VEGF did not (OS HR 1.01). Is there something to the VEGF/PDL1 combination in some settings? #LCSM #OncoAlert
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.